Methods | On March 13, 2013, a nurse discovered "floaters" in a bag of MgSO 4 . The hospital pharmacy immediately recalled all units of MgSO 4 produced by the compounding pharmacy and found floaters in a second lot of MgSO 4 recalled from a different hospital ward. The following day, pharmacy personnel recalled all 12 000 units of 44 types of products received from the compounding pharmacy from all patient care areas at the hospital and at 2 other system-related hospitals. Appropriate state agencies, the US Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC) were notified. Products from the compounding pharmacy were sequestered and examined by hospital pharmacy employees and FDA personnel for visible evidence of contamination, and samples were obtained for investigation by the FDA and CDC. The hospital microbiology laboratory performed DNA sequencing of material from the contaminated MgSO 4 .
Because multiple lots of MgSO 4 produced by the compounding pharmacy, including lots without visible contamination, were in use at the hospital concurrently, and lot numbers are not embedded in medication barcodes recorded in patient medical records, we could not identify only those patients who received MgSO 4 from contaminated lots. Therefore, a list of all patients who received MgSO 4 during the exposure period was generated. Hospital personnel notified potentially exposed patients by telephone and certified letter and informed their physicians by telephone. Prophylactic voriconazole was administered to patients with allogeneic stem cell transplants who were potentially exposed.
From mid-March through mid-June 2013, medical records of potentially exposed patients who were readmitted were reviewed for evidence of fungal infection, and microbiology laboratories at the 3 system hospitals reported growth of any mold from sterile body sites twice weekly to the infection control program.
Results | DNA sequencing performed by the hospital microbiology laboratory directly on particulate material from contaminated bags and sequencing of fungal growth recovered from 2 lots of contaminated MgSO 4 was consistent with Hamigera spp, subsequently identified by the CDC as Hamigera insecticola. Sequencing of fungal growth from 1 of the 2 lots also yielded an Aspergillus-like organism, identified by the CDC as Neosartorya hiratsukae. Investigations by the CDC and a reference laboratory used by the compounding pharmacy found that 4 lots of MgSO 4 and a lot of dexamethasone sodium phosphate were contaminated with fungi, including Penicillium chrysogenum and Penicillium rubens ( Table 1) .
A total of 1309 patients and 460 physicians were notified regarding possible exposures to contaminated MgSO 4 . As of mid-June 2013, responses to hotline calls, laboratory-based surveillance, and review of 545 readmissions of potentially exposed patients revealed no fungal infections attributable to the contaminating fungi. The hospital's response involved an estimated 14 915 hours of personnel time, and estimated costs to the hospital system were $874 989 ( Table 2 ). An FDA investigation revealed that the source of contamination was the compounding pharmacy, where all contaminated products prepared for our hospital were compounded on a separate (unique) laminar flow work bench, and uncovered unsanitary conditions and numerous violations of good manufacturing practice requirements for drugs. 4 Invited Commentary page 613 
Sexual Activity in Midlife Women: Importance of Sex Matters
Sexual function is associated with health-related quality of life (HRQoL). 1, 2 Understanding the factors that affect aging women's sexual activity has implications for maintenance of HRQoL in this population.
In this study, we used a longitudinal cohort to examine the factors that predict maintenance of sexual activity among midlife women. We hypothesized that higher sexual function and higher importance of sex at baseline would predict maintenance of sexual activity.
Methods | Do Stage Transitions Result in Detectable Effects
(STRIDE) is a longitudinal cohort study of women ages 40 to 65 years enrolled in 2005 from a general internal medicine practice. All English-speaking women who completed written informed consent were enrolled. This study was approved by the University of Pittsburgh's institutional review board. Women completed annual questionnaires regarding demographic variables, menopausal status and symptoms, and medical comorbidities. In year 4 of the study, women completed the Female Sexual Function Index (FSFI). 3 Lower scores indicate worse sexual function. Importance of sex was assessed by a single question. Menopausal status was assigned based on selfreported bleeding history. Body mass index and medication use were abstracted from the electronic health record. The primary outcome was sexual activity at year 8, assessed by the question: "During the past 6 months, have you engaged in any sexual activities with a partner?" Women who did not answer the questions on sexual function or who answered "No sexual activity in the prior 4 weeks" on any FSFI question were excluded.
Descriptive statistics were used to compare sexually active and inactive women at baseline. We used univariable logistic regression models to examine characteristics associated with sexual activity maintenance at study year 8. Variables that may change over time were examined longitudinally using random effects mixed models. Variables that attained clinical or marginal statistical significance (P < .20) were entered into a multivariable model. 
